Pfizer Inc. (PFE)

52.55
0.08 0.15
NYSE
Prev Close 52.47
Day Low/High 52.48 / 53.70
52 Wk Low/High 38.48 / 61.71
Exchange NYSE
Shares Outstanding 5610.90B
Market Cap 294.40B
P/E Ratio 23.58
Div & Yield N.A. (N.A)

Latest News

A Thought on XBI

I have been accumulating a position in SPDR S&P Biotech ETF .   Pfizer's proposed acquisition for Biohaven Pharmaceutical (+73% in after hours) may help the effort today.   I plan to add to XBI and FibroGen today (good results).

As Pfizer Faces a Period of Volatility, Here's My Plan for the Shares

As Pfizer Faces a Period of Volatility, Here's My Plan for the Shares

There will have to be an adjustment made to their Covid vaccine and others at some point.

Premarket Movers

Upside - +12% (receives FCC license for US-based testing of BlueWalker 3 satellite) - +9.5% (Activist Elliott sends letter to the Board of Western Digital; Offers $1B+ of incremental equity capital to facilitate separation of Flash business) -  +9.3...

Beijing's Covid Outbreak Sends Chinese Stocks South

Beijing's Covid Outbreak Sends Chinese Stocks South

The CSI 300 plunged to its lowest level in two years as residents of the Chinese capital stripped grocery store shelves bare amid lockdown fears.

Relief Rally, Charting the Indexes, Fed Talk, Taiwan Semi, Musk Bids for Twitter

Relief Rally, Charting the Indexes, Fed Talk, Taiwan Semi, Musk Bids for Twitter

The market roared, but the pros did not tag along in size. They either have to catch up, or they are just not coming.

Just a Spoonful of Profits to Help the Merck Go Down

Just a Spoonful of Profits to Help the Merck Go Down

Here's where I think MRK can go and how to play it.

With This Pharma Value Play, the Market's Punishment Doesn't Fit the Crime

With This Pharma Value Play, the Market's Punishment Doesn't Fit the Crime

The growth crowd has moved on, leaving a stock trading at attractive levels.

This Stock Has Had Good 2-Year Run -- But That May Be About to Change

This Stock Has Had Good 2-Year Run -- But That May Be About to Change

You might not immediately think of this name as a big winner over the last two years.

Looking for a Pairs Trade? Go Long China, Short Europe

Looking for a Pairs Trade? Go Long China, Short Europe

Here's why China is winning.

Blue Monday, Technical Damage, Death Cross, FOMC, China, Raskin, Lockheed Martin

Blue Monday, Technical Damage, Death Cross, FOMC, China, Raskin, Lockheed Martin

The Nasdaq Composite suffered a 'death cross' back in mid-February and what happened after that is now clear to see.

Pricing in Ugly, Ukraine War, China-Russia, Markets, Week Ahead, Q4 Performance

Pricing in Ugly, Ukraine War, China-Russia, Markets, Week Ahead, Q4 Performance

It appears that miners, drillers and defense contractors are still the places to be from an equity perspective. Everything else is a trade.

Corporate Fun

Selections from next week's lineup of events:  Monday  Kohl's virtual investor day. Pfizer  participates in Cowen's 42nd Annual Healthcare Conference.  Tuesday  Parker Hannifin virtual meeting with investors and analysts. Microsoft  participates at ...

Market Fun House, Bond Yields, Nord Stream 2, Raytheon, Steel, No Dice Nvidia

Market Fun House, Bond Yields, Nord Stream 2, Raytheon, Steel, No Dice Nvidia

I had actually worried a bit that Arm was going to take Jensen Huang's eye off of the ball. That worry can now be put to bed.

Viagra to Vaccines: 8 Healthcare Favorites for 2022

Viagra to Vaccines: 8 Healthcare Favorites for 2022

Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.

Spiking Yields, Catastrophic Miss, Welcome to Week 3, Bat Signal? Walmart Crypto

Spiking Yields, Catastrophic Miss, Welcome to Week 3, Bat Signal? Walmart Crypto

In short, Friday was simply an absolute disaster for the U.S. in macroeconomic terms.

Top Stock Picks for 2022 in Biotech and Genetics

Top Stock Picks for 2022 in Biotech and Genetics

Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.

Markets, Treasuries, Taxes, 2022 Expectations, FOMC, 2 Stocks to Watch

Markets, Treasuries, Taxes, 2022 Expectations, FOMC, 2 Stocks to Watch

Negative returns for 2022? It's a midterm election year. We will see increased volatility. Anything is possible, and it would not surprise me.

Markets, Data Dump, Student Loans, TikTok, Merck, Trading Salesforce

Markets, Data Dump, Student Loans, TikTok, Merck, Trading Salesforce

Friday might be a market holiday, but it became obvious on Wednesday that trading volumes had started to truly dwindle.

These 2 Undervalued Biotechs Are Ripe for Acquisition

These 2 Undervalued Biotechs Are Ripe for Acquisition

Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.

Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple

Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple

Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.

Pfizer Gets Chai!

Pfizer bets on medical cannabis.

Omicron Threat, Slowing Economic Activity, Week Ahead, 4 Trading Thoughts

Omicron Threat, Slowing Economic Activity, Week Ahead, 4 Trading Thoughts

Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.

A 'Here We Go Again'-Kinda Day Winds Down

Markets ended mixed for the day as options expire. Pfizer continues to pick up bulls, it seems. Cantor Fitzgerald believes the company's Covid-19 vaccine and hotly anticipated antiviral drug could generate combined peak sales of between $50 billion ...

Can Biotech Keep This Up? Also, Unions a Tall Order for Starbucks?

Market has not moved much since our last update. Biotech continues to be one of the strongest sectors today with the SPDR S&P Biotech ETF  up nearly 5% on the day. It will be interesting to see if biotech can hold its gains into the close given it i...

Eye on Skyworks, a Potential Acquisition and Omicron

Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...

We See Multiple Boosts Ahead for Pfizer

We See Multiple Boosts Ahead for Pfizer

We have new price targets for soaring shares of PFE. Let's check the charts.

The Bedraggled Biotech Sector Finally Offers a Glimmer of Hope

The Bedraggled Biotech Sector Finally Offers a Glimmer of Hope

Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022

The Most (Mr.) Wonderful Time of the Year for Dividend Income

The Most (Mr.) Wonderful Time of the Year for Dividend Income

The top-10 holdings of Kevin O'Leary's O'Shares FTSE U.S. Quality Dividend ETF are an interesting source of quality dividend growth stocks.